ATE557094T1 - Krebsspezifische promotoren - Google Patents

Krebsspezifische promotoren

Info

Publication number
ATE557094T1
ATE557094T1 AT05767457T AT05767457T ATE557094T1 AT E557094 T1 ATE557094 T1 AT E557094T1 AT 05767457 T AT05767457 T AT 05767457T AT 05767457 T AT05767457 T AT 05767457T AT E557094 T1 ATE557094 T1 AT E557094T1
Authority
AT
Austria
Prior art keywords
cancer
specific
control sequences
specific control
combination
Prior art date
Application number
AT05767457T
Other languages
English (en)
Inventor
Mien-Chie Hung
Chi-Ping Day
Kun-Ming Rau
Xiaoming Xie
Zheng Li
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE557094T1 publication Critical patent/ATE557094T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
AT05767457T 2004-04-02 2005-04-01 Krebsspezifische promotoren ATE557094T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55911104P 2004-04-02 2004-04-02
PCT/US2005/011067 WO2005103251A2 (en) 2004-04-02 2005-04-01 Cancer specific promoters

Publications (1)

Publication Number Publication Date
ATE557094T1 true ATE557094T1 (de) 2012-05-15

Family

ID=35057078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05767457T ATE557094T1 (de) 2004-04-02 2005-04-01 Krebsspezifische promotoren

Country Status (9)

Country Link
US (2) US7816131B2 (de)
EP (1) EP1737966B1 (de)
JP (1) JP2007535315A (de)
CN (1) CN1997745A (de)
AT (1) ATE557094T1 (de)
DK (1) DK1737966T3 (de)
ES (1) ES2385492T3 (de)
PT (1) PT1737966E (de)
WO (1) WO2005103251A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US7709253B2 (en) * 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
WO2008070448A2 (en) * 2006-11-22 2008-06-12 Board Of Regents, The University Of Texas System Cancer-specific promoters
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
WO2010097419A1 (en) 2009-02-25 2010-09-02 Fundació Privada Centre De Regulació Genòmica (Crg) Conditionally replicating adenovirus effective in the treatment of tumors
JP5733705B2 (ja) * 2009-03-30 2015-06-10 国立大学法人 岡山大学 特異的プロモーターの活性を上昇させるシステム及び該システムを保持したベクター
US10738324B2 (en) 2010-09-30 2020-08-11 Kagoshima University Growth-regulated viral vector containing the aurora kinase promoter
SG191246A1 (en) * 2010-12-24 2013-07-31 Agency Science Tech & Res Modified human cmv promoters that are resistant to gene silencing
CN102352369A (zh) * 2011-07-06 2012-02-15 中山大学肿瘤防治中心 一种在肿瘤细胞中高效高特异表达靶基因的载体t-visa
CN102327624A (zh) * 2011-09-28 2012-01-25 中山大学肿瘤防治中心 一种可高效在体内外转染基因的新型脂质体及其制备方法
IN2014CN02581A (de) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
CN102716498A (zh) * 2012-03-12 2012-10-10 中山大学肿瘤防治中心 一种可高效高特异灭杀p53基因突变型乳腺癌细胞的药物脂质体
EP3004357A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Peg-prom-vermittelte oberflächenexpression von avidin/streptavidin
EP3003022B1 (de) 2013-06-04 2017-11-22 Virginia Commonwealth University Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika
EP3003393A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Dreiteilige theranostische krebs-nukleinsäurekonstrukte
EP3004153B1 (de) 2013-06-04 2019-10-30 Virginia Commonwealth University Rekombinantes cytokin für eine krebstherapie
WO2014197586A1 (en) 2013-06-04 2014-12-11 Virginia Commonwealth University Mda-9/syntenin promoter to image and treat metastatic cancer cells
EP3344034A1 (de) * 2015-09-02 2018-07-11 Regeneron Pharmaceuticals, Inc. Nagetiermodell von prostatakrebs
JOP20190166A1 (ar) * 2017-01-05 2019-07-02 Univ Texas استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
TW202115126A (zh) 2019-06-11 2021-04-16 美商舒爾人類基因療法公司 用於治療血漿激肽釋放酶失調所介導之疾病的抗體腺相關病毒載體遞送
US20230043051A1 (en) 2019-10-23 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
JP2023554066A (ja) 2020-12-16 2023-12-26 武田薬品工業株式会社 血漿カリクレインの制御不全によって媒介される疾患の処置のための抗体のアデノ随伴ウイルスベクター送達

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
AU5742198A (en) 1997-02-03 1998-08-25 Commonwealth Scientific And Industrial Research Organisation Tissue specific promoters
AUPO492397A0 (en) 1997-02-03 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Prostate specific promoters
GB9703633D0 (en) * 1997-02-21 1997-04-09 Imp Cancer Res Tech Cancer therapy
WO1999016787A1 (en) 1997-09-26 1999-04-08 Washington University Cell death agonists
US6313373B1 (en) 1998-10-30 2001-11-06 Case Western Reserve University Tissue specific promoters and transgenic mouse for the screening of pharmaceuticals
US6716824B1 (en) * 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
JP2001218587A (ja) 2000-02-08 2001-08-14 Academia Sinica 最小ｃｍｖプロモーターを含むバキュロウイルス
AU2001266740A1 (en) * 2000-06-06 2001-12-17 Genelabs Technologies, Inc. Promoters for regulated gene expression
EP1207204A1 (de) 2000-11-16 2002-05-22 KWS Saat AG Gewebespezifische Promotoren aus der Zuckerrübe
DE10209451A1 (de) * 2002-03-05 2003-09-18 Universitaetsklinikum Hamburg Spezifische Genexpression in Kolonkarzinom-Zell-Linien
WO2004089981A2 (en) * 2003-04-02 2004-10-21 Board Of Regents, The University Of Texas System Antitumor effect of mutant bik

Also Published As

Publication number Publication date
US20080286860A1 (en) 2008-11-20
US7816131B2 (en) 2010-10-19
JP2007535315A (ja) 2007-12-06
EP1737966B1 (de) 2012-05-09
US20050260643A1 (en) 2005-11-24
WO2005103251A3 (en) 2006-04-27
EP1737966A2 (de) 2007-01-03
ES2385492T3 (es) 2012-07-25
DK1737966T3 (da) 2012-07-09
US7723104B2 (en) 2010-05-25
CN1997745A (zh) 2007-07-11
WO2005103251A2 (en) 2005-11-03
PT1737966E (pt) 2012-08-06

Similar Documents

Publication Publication Date Title
ATE557094T1 (de) Krebsspezifische promotoren
IL258880A (en) Compounds of diarylhydantoin
AU2022259847B2 (en) AXL-specific antibody-drug conjugates for cancer treatment
PH12019501959A1 (en) Therapeutic rna
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
MX2010003658A (es) Sistema quirurgico no invasivo basado en fotones que incluye control celular automatico y erradicacacion por control de proalimentacion pre-calculada mas control de retroalimentacion de imagen para suministro enfocado de energia.
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
SG170809A1 (en) Diarylthiohydantoin compounds
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
NZ588435A (en) Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
WO2010054397A3 (en) N-cadherin: target for cancer diagnosis and therapy
ZA202106392B (en) Therapeutic rna for prostate cancer
WO2008070448A3 (en) Cancer-specific promoters
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2009126315A3 (en) Macrocyclic compounds and methods of treatment
MX2021012931A (es) Polipeptidos multiespecificos activables y terapeuticos con semivida extendida.
WO2009038771A3 (en) Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
WO2008144659A3 (en) Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers
ATE552887T1 (de) Tumorspezifischer vektor für die gentherapie
ATE443138T1 (de) Hemmung der expression von spag9 mit sirnas
TH105533B (th) พาราพ็อกซ์ไวรัสร่วมกันกับสารเคมีบำบัดที่เป็นพิษต่เซลล์ดั้งเดิมเป็นการรักษาทางชีวเคมีสำหรับการบำบัดมะเร็ง
TN2009000491A1 (en) Use of heterosidic flavonoid derivatives for therapy of stem cell cancers